Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canada-based drug development company Migenix has obtained positive results on the effectiveness of its lipopeptide anti-bacterial product candidate, MX-2401, in accepted rodent models of pneumonia and soft tissue infections.
Subscribe to our email newsletter
This injectable compound is in preclinical development for the treatment of serious gram- positive infections. The company recently received a $9.3 million investment commitment from the Government of Canada’s Technology Partnerships Canada program towards the development of MX-2401.
The studies proved the ability of MX-2401 to kill streptococcus pneumoniae in the lungs and/or thighs of infected mice, a model used widely to predict efficacy in human pneumonia and complicated skin and soft tissue infections. The data also confirmed the efficacy of MX-2401 against another serious gram-positive pathogen, staphylococcus aureus.
MX-2401 is a novel lipopeptide with potential as an improved treatment of patients infected with life-threatening strains of streptococcus pneumoniae and staphylococcus. In vitro studies have shown that MX-2401 is potent against these clinically important bacteria which are the cause of many hospital-acquired pneumonias and wound infections.
Dr William Craig at the University of Wisconsin Medical School said: “MX-2401 has several attractive features as a possible treatment for resistant gram-positive infections. Based on results to date, the compound could have the potential to be used in treating complicated skin and soft tissue infections, pneumonia and bacteremia due to resistant gram-positive bacteria, including vancomycin-resistant enterococci”.